Waters Corporation has released the Xevo Charge Detection Mass Spectrometer (CDMS), a significant innovation aimed at overcoming the analytical challenges of today’s complex biomolecular therapies. This tool allows lab managers and teams to confidently analyze mega-mass molecules with greater speed and efficiency, supporting critical decisions in R&D and process development.
With next-gen therapies like viral vectors and mRNA vaccines requiring more nuanced analysis, the Xevo CDMS offers a robust solution that:
- Reduces sample volume requirements by up to 100-fold.
- Achieves precise mass analysis at concentrations as low as 10^10 vp/mL.
- Generates results in under ten minutes.
- Works seamlessly across discovery, development, and manufacturing workflows.
"We are proud to introduce the first-of-its-kind Xevo Charge Detection Mass Spectrometer, enabling the precise analysis of previously unmeasurable molecules," said Udit Batra, Ph.D., President and CEO of Waters Corporation.
Enhancing Lab Operations
The Xevo CDMS is powered by GxP-ready waters_connect™ Software and features the Electrostatic Linear Ion Trap (ELIT) for direct ion measurement. This eliminates the need for complex deconvolution or digestion workflows, streamlining lab operations.
Timothy Fenn, Ph.D., VP of Analytical Development and QC at Lexeo Therapeutics, added, "With CDMS, we're asking questions we didn't know we could ask. It's a game-changer for our analytical workflows."
Why It Matters for Lab Managers:
- Accelerates time-to-data for critical therapies.
- Increases compliance readiness and analytical confidence.
- Reduces operational bottlenecks in high-throughput settings.
Available for order now, the Xevo CDMS supports labs in staying ahead of therapeutic innovation while optimizing day-to-day performance.
